ESMO Congress 2026

October 23–27, 2026 · Madrid · 176 items

Madrid floor. One post is one item; several people on the same trial or drug become a heat probe. The floor is paged by day; prelude discussion sits on the prelude board. Abstracts are linked, not reprinted, and other people's slides are not posted.

Oct 21Wed

Wednesday · 11 items

20:00
HHorinouchi@HHorinouchiScore6060
🆙 #ESMO26 Proffered Paper I: #LCSM Mets 🔥SARON: Primary Results of a Randomised-Controlled Trial of Consolidation Radiotherapy for Synchronous Oligometastatic Non-Small Cell Lung C…
NCT02417662 2613O 0MO #LCSMHeat 10 likes0 replies1 repost
19:11
GlopesMd@GlopesMdScore6060
Five lung cancer trials to watch at #ESMO26: DeLLphi-305 KRAScendo 1 SAFFRON OptiTROP-Lung04 OptiTROP-Lung06 Encouraging signals. Full data matter: survival, CNS activity, toxici…
Same topic DELLPHI-305 · 5 people KRASCENDO SAFFRON #LCSMHeat 6647 likes0 replies19 reposts
18:36
ozdogan_md@ozdogan_mdScore6060
After osimertinib, can we target resistance rather than move straight to chemo? SAFFRON: osimertinib + savolitinib vs platinum–pemetrexed in EGFRm/MET-OE/AMP NSCLC. PFS/OS toplines…
SAFFRON LBA6 osimertinib savolitinib MET #LCSMHeat 95 likes0 replies4 reposts
18:01
OncoAlert@OncoAlertScore6060
🚨 #ESMO26 Lung Cancer: Top Ten by @OncoAlert 🫁 The abstracts our faculty picked as must-know from Madrid 👇 1️⃣ DeLLphi-305 (LBA3): tarlatamab + durvalumab, 1L maintenance in ES-S…
Same topic DELLPHI-305 · 5 people KRASCENDO SAFFRON SANOVO LBA3 LBA5 LBA6 LBA67 LBA66Heat 6237 likes0 replies25 reposts
16:00
OncoAlert@OncoAlertScore6060
OncoAlert 4Sight Abstracts to be Presented at #ESMO26 2875O: Pembrolizumab or Placebo Plus Concurrent Definitive Chemoradiotherapy in Esophageal and Gastroesophageal Junction (GE…
Same topic KEYNOTE-975 · 3 people 2875O pembrolizumabHeat 2117 likes0 replies4 reposts
04:29
LungCancerEu@LungCancerEuScore6060
No agreed treatment once small cell #lungcancer comes back. Finding from RESONANCE, to be presented at #ESMO26 by @nicogirardcurie . 623 people with ext-stage #SCLC in France, G…
#LUNGCANCER #SCLC #LCSMHeat 1916 likes0 replies3 reposts
03:21
ATarhiniMDPhD@ATarhiniMDPhDScore6060
#ESMO26 Abstracts – Among ours | A surveillance, epidemiology & end results (#SEER) #Medicare analysis of outcomes & treatment patterns in #nonmetastatic #melanoma | Presenting thi…
#SEER #MEDICARE #NONMETASTATIC #MELANOMA #MADRID #SPAINHeat 73 likes0 replies4 reposts
03:05
KolPulseAI@KolPulseAIScore6060
The ten trials oncologists are waiting for at #ESMO26, ranked by how many physicians posted about each one before Madrid. Top three: VOLGA, INTerpath-001, DeLLphi-305. Flagged by @…
Same topic VOLGA · 6 people INTERPATH-001 DELLPHI-305Heat 53 likes0 replies2 reposts
02:42
ATarhiniMDPhD@ATarhiniMDPhDScore6060
#ESMO26 Abstracts – Among ours | #Realworld stage III #melanoma outcomes following #neoadjuvant #nivolumab + #relatlimab or #nivolumab + #ipilimumab | To be presented by Mike Posto…
nivolumab relatlimab ipilimumab #REALWORLD #MELANOMA #NEOADJUVANT #NIVOLUMAB #RELATLIMABHeat 64 likes0 replies2 reposts
01:01
ATarhiniMDPhD@ATarhiniMDPhDScore6060
#ESMO26 Abstracts Released - Among ours | Host #InheritedGeneticVariation & the risk of #Hepatitis following #ImmuneCheckpoint #Immunotherapy (ICI) of #Melanoma | Presenting this w…
#INHERITEDGENETICVARIATION #HEPATITIS #IMMUNECHECKPOINT #MELANOMA #MADRID #SPAINHeat 52 likes0 replies3 reposts
00:00
LillyOncMed@LillyOncMedScore6060
Learn more about Model-Informed Phase 3 Dose Selection for Antibody-Drug Conjugate (ADC) Sofetabart Mipitecan (Sofe-M): First Prospective Application of a Clinical Utility Index. …
1016P mipitecanHeat 54 likes0 replies1 repost

Oct 20Tue

Tuesday · 11 items

23:04
GuardantHealth@GuardantHealthScore6060
Strong collaborations drive new possibilities in #CancerCare. At #ESMO26, we, along with our research collaborators, will present 25 abstracts, including 5 rapid oral presentatio…
#CANCERCAREHeat 42 likes0 replies2 reposts
20:27
DrRishabhOnco@DrRishabhOncoScore6060
🚨 ESMO 2026 | TOP 10 GU CANCER TRIALS TO WATCH! From perioperative immunotherapy and AR pathway intensification to HIF-2α inhibition and long-term survival updates, GU oncology is…
Same topic DASL-HICAP · 3 people CAPITELLO-281 VOLGA KEYNOTE-866 LITESPARK-011 LITESPARK-012 KEYNOTE-564 KEYNOTE-B15 LBA4Heat 3528 likes0 replies7 reposts
19:42
ozdogan_md@ozdogan_mdScore6060
DASL-HiCaP tests darolutamide + ADT + RT in very-high-risk localised prostate cancer, with MFS as the primary endpoint. The result magnitude is still pending. Key question: will th…
Same topic DASL-HICAP · 3 people #PROSTATECANCERHeat 105 likes0 replies5 reposts
18:58
chuminhua432@chuminhua432Score6060
#ESMO2026 abstract: 🇨🇳Innovent’s EGFR/B7-H3 Bispecific ADC IBI3001 Posts 28% ORR in Phase 1, Reaches 87.5% in Biomarker-Positive Patients (1001O) IBI3001 carries exatecan, a topoi…
NCT06349408 1001O exatecan EGFRHeat 1917 likes0 replies2 reposts
18:41
chuminhua432@chuminhua432Score6060
#ESMO2026 abstract: 🇨🇳CSPC’s HER3 ADC SYS6023 Shows Preliminary Activity in Solid Tumors, Sets RP2D at 5.5 mg/kg First-in-human Phase 1 data for SYS6023 (1028P) SYS6023 is HER3-t…
1028PHeat 85 likes0 replies3 reposts
18:12
OncoAlert@OncoAlertScore6060
🚨 #ESMO26 Breast Cancer: Top Ten by @OncoAlert 🎗️ The abstracts our faculty flagged as must-know from MADRID🇪🇸 👇 1️⃣ PANKU-Breast01 (LBA50): iza-bren in HR+/HER2− mBC 2️⃣ FOURLIG…
Same topic PANKU-BREAST01 · 2 people FOURLIGHT-1 NATALEE APEX-BREAST01 KEYNOTE-B49 HORIZON-BREAST06 POSTMONARCH DESTINY-BREAST09 LBA50Heat 7552 likes0 replies23 reposts
18:12
chuminhua432@chuminhua432Score6060
#ESMO2026: Biokin (SystImmune) ’s Iza-bren + Osimertinib Delivers 100% ORR in 2.5 mg/kg Cohort of 1L EGFR-Mutated NSCLC (2575P) Among 40 patients receiving iza-bren at 2.5 mg/kg p…
2575P osimertinib EGFRHeat 2921 likes0 replies8 reposts
15:02
dr_yakupergun@dr_yakupergunScore6060
#ESMO26 | PERSEE – Phase III In advanced NSCLC with PD-L1 ≥50%, adding chemotherapy to pembrolizumab improved median PFS from 6.9 to 16.1 months (HR 0.56). The numerical OS differ…
Same topic pembrolizumab · 2 peopleHeat 5442 likes0 replies12 reposts
04:53
DaisukeKotani@DaisukeKotaniScore6060
#ESMO26 | 2894P Retrospective study of 1L Tx for ESCC with supraclavicular lymph node metastasis Chemo + ICI (CI) vs CRT (CCRT) vs Chemo + ICI followed by RT (CIRT) ▪️3y-OS: 52.1% …
2894PHeat 137 likes0 replies6 reposts
04:27
fangdisun@fangdisunScore6060
#ESMO26 starts in less than a week! My summary and comments on notable #HNcancer studies, with several that help contextualize ongoing Ph3 trials in 1L R/M setting. ‼️ None immedia…
#HNCANCERHeat 106 likes0 replies4 reposts
02:04
GlopesMd@GlopesMdScore6060
One of my most anticipated #ESMO26 presentations: Krascendo 1 (LBA5) — phase III divarasib vs sotorasib/adagrasib in previously treated KRAS G12C+ NSCLC. Roche reports positive P…
KRASCENDO LBA5 divarasib sotorasib adagrasib KRASHeat 2011 likes0 replies9 reposts

Oct 19Mon

Monday · 8 items

22:54
dr_yakupergun@dr_yakupergunScore6060
#ESMO26 | Bulumtatug Fuvedotin – Phase II In metastatic TNBC previously treated with TOP1 inhibitor-based ADCs, the Nectin-4-targeted, MMAE-based ADC bulumtatug fuvedotin achieved…
Heat 3323 likes0 replies10 reposts
21:47
RobertoBoreaMD@RobertoBoreaMDScore6060
Liquid biopsy abstracts I would not miss at #ESMO26 in Madrid 🩸 17 abstracts: ctDNA dynamics on targeted therapy, ctDNA clearance with perioperative IO, ultrasensitive MRD, early d…
Heat 7346 likes0 replies27 reposts
19:35
IovanceBio@IovanceBioScore6060
Madrid, here we come! 🇪🇸 Iovance’s 5 abstracts at #ESMO26 (Oct 23–27) showcase the TIL platform, including 2 orals in frontline advanced melanoma 🔬 and refractory soft tissue sarco…
Heat 8572 likes0 replies13 reposts
19:04
boutrosand@boutrosandScore6060
What to watch at #ESMO26 in melanoma and skin cancers 👇 INTerpath-001 (LBA1), STARBOARD, HBI-8000-303, TIL, NADINA, C-POST, ADMEC-O, MATISSE 2. Plus ADCs after anti-PD-1, HER3-DX…
Same topic INTERPATH-001 · 11 people STARBOARD NADINA LBA1 2073RO 2074RO enfortumab pembrolizumab HBI-8000Heat 2014 likes0 replies6 reposts
18:37
chuminhua432@chuminhua432Score6060
#ESMO2026 abstract: 🇨🇳Innovent’s IBI363 + Chemotherapy (PDC) Shows mPFS Not Reached in 1L NSCLC (1044P) Study design - 80 previously untreated patients with advanced NSCLC withou…
1044P EGFR ALK ROS1Heat 75 likes0 replies2 reposts
18:09
chuminhua432@chuminhua432Score6060
#ESMO2026 abstract: 🇨🇳Keymed’s CDH17 ADC CM518D1 Posts 33.3% ORR in Colorectal Cancer (1015P) The ongoing open-label, multicenter Phase 1/2 study (NCT07019779) is evaluating its s…
NCT07019779 1015PHeat 1714 likes0 replies3 reposts
17:30
OncoAlert@OncoAlertScore6060
🚨 #ESMO26 GU Oncology — Top picks by OncoAlert 🎯 #BladderCancer : VOLGA, KEYNOTE-B15, ENERGIZE, KEYNOTE-866 #ProstateCancer: DASL-HiCaP, CAPItello-281, PROTEUS #KidneyCancer: LITE…
Same topic VOLGA · 6 people KEYNOTE-B15 KEYNOTE-866 DASL-HICAP CAPITELLO-281 LITESPARK-011 ivonescimab #BLADDERCANCER #PROSTATECANCERHeat 9058 likes0 replies32 reposts
17:06
DaisukeKotani@DaisukeKotaniScore6060
#ESMO26 | 788RO ECLYPse: Ph2 EC beyond progression in combination with FOLFIRI in BRAF V600E mCRC @myESMO @OncoAlert
788RO BRAFHeat 97 likes0 replies2 reposts